⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18344021 | 0.89 | — | — | |
| SCHEMBL18344069 | 0.89 | — | — | |
| SCHEMBL18344131 | 0.87 | — | — | |
| SCHEMBL18344012 | 0.86 | — | — | |
| SCHEMBL18344111 | 0.85 | — | — | |
| SCHEMBL18344172 | 0.83 | — | — | |
| SCHEMBL18344240 | 0.82 | — | — | |
| SCHEMBL20296780 | 0.81 | HDAC6 (0.45) | — | |
| SCHEMBL18344119 | 0.81 | — | — | |
| SCHEMBL18344250 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | claimed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | claimed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | claimed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | claimed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | claimed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | claimed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | claimed |
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | disclosed |